BACKGROUND:Type 2 diabetes is a complex metabolic disorder often requiring combination therapy for optimal glycaemic control. This study assessed the efficacy and safety of orforglipron, an oral, non-peptide GLP-1 receptor agonist, versus dapagliflozin, an oral SGLT2 inhibitor, in participants with type 2 diabetes and inadequate glycaemic control with metformin. METHODS:This 40-week, phase 3, multicentre, open-label (orforglipron dose-blinded), randomised study was conducted in 73 sites across six countries. The study included adults with type 2 diabetes using metformin (≥1500 mg/day) with glycated haemoglobin (HbA1c) concentrations between 7·0% and 10·5% (53-91 mmol/mol), stable bodyweight (±5%), and a BMI of 23·0 kg/m2 or more. Participants were randomly assigned in a 1:1:1:1 ratio to receive once-daily oral orforglipron (3 mg, 12 mg, or 36 mg) or dapagliflozin 10 mg. The primary endpoint was change from baseline in HbA1c at week 40, using a non-inferiority margin of 0·3% for orforglipron versus dapagliflozin; analysis was based on the treatment-regimen estimand (data obtained regardless of study intervention discontinuation or initiation of additional glucose-lowering agents). The treatment regimen estimand was the primary estimand, with the efficacy estimand considered supportive. Safety was assessed in all randomised participants who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov (NCT06192108, completed). FINDINGS:From Jan 10, 2024, to Sept 26, 2025, 1404 adults were assessed and 962 participants were randomly assigned to orforglipron 3 mg (n=240), 12 mg (n=241), or 36 mg (n=241), or dapagliflozin 10 mg (n=240). The baseline population included 474 (49%) females and had a mean age of 56·1 years (SD 11·5), HbA1c of 8·14% (1·04), type 2 diabetes duration of 8·0 years (6·7), and BMI of 32·6 kg/m2 (6·6). At week 40, for the treatment regimen estimand, all orforglipron doses were non-inferior to dapagliflozin in reducing HbA1c. Change from baseline in mean HbA1c was -1·23% (SE 0·08), -1·50% (0·08), and -1·56% (0·09) with orforglipron 3 mg, 12 mg, and 36 mg, respectively, versus -0·81% (0·07) with dapagliflozin 10 mg; estimated treatment difference versus dapagliflozin was -0·42% (95% CI -0·62 to -0·23), -0·70% (-0·90 to -0·49), and -0·75% (-0·96 to -0·55) with orforglipron 3 mg, 12 mg, and 36 mg, respectively (all p<0·0001). The most frequent adverse events associated with orforglipron were mild-to-moderate gastrointestinal events, observed in 112 (47%) of 240 participants receiving orforglipron 3 mg, 112 (46%) of 241 receiving 12 mg, and 130 (54%) of 241 receiving 36 mg, versus 29 (12%) of 240 receiving dapagliflozin. More study intervention discontinuations were observed with orforglipron 3 mg (35 [15%] of 240), 12 mg (44 [18%] of 241), and 36 mg (47 [20%] of 241) than with dapagliflozin (14 [6%] of 240). No severe episode of hypoglycaemia was reported. INTERPRETATION:Orforglipron demonstrated superior glycaemic control compared with dapagliflozin, with a tolerability profile consistent with the GLP-1 receptor agonist class, including increased rates of discontinuation due to adverse events, positioning it as a potential effective oral treatment option for type 2 diabetes. FUNDING:Eli Lilly and Company.
The Canadian Stroke Best Practice Recommendations 7 th edition update of the Rehabilitation, Recovery and Community Participation module is presented in three parts. This publication, Part One of the series, reflects the growing and changing body of research evidence available to guide planning, ongoing screening and assessment, management, education, and support of individuals with stroke, their families, and caregivers. This module provides guidance for the planning and delivery of coordinated and seamless systems of care from acute stroke onset to return to community settings by an interdisciplinary team of healthcare providers with expertise in stroke. These recommendations were developed with active involvement of people with lived experience of stroke at all phases. These recommendations are intended to support the progress achieved during the initial recovery stages and enable individuals with stroke to resume life roles and leisure activities as best as possible, to achieve optimal recovery goals. Evidence for effective rehabilitation therapies and support for individuals with stroke and their families continues to emerge and gaps in knowledge should drive future research.
Ultra-rapid-acting insulin analogs (URAA) are a further development and refinement of rapid-acting insulin analogs. Because of their adapted formulation, URAA provide an even faster pharmacokinetics and thus an accelerated onset of insulin action than conventional rapid-acting insulin analogs, allowing for a more physiologic delivery of exogenously applied insulin. Clinical trials have confirmed the superiority of URAA in controlling postprandial glucose excursions, with a safety profile that is comparable to the rapid-acting insulins. Consequently, many individuals with diabetes mellitus may benefit from URAA in terms of prandial glycemic control. Unfortunately, there are only few available recommendations from authoritative sources for use of URAA in clinical practice. Therefore, this expert consensus report aims to define populations of people with diabetes mellitus for whom URAA may be beneficial and to provide health care professionals with concrete, practical recommendations on how best to use URAA in this context.
BOUQUET (NCT04931342) is an ongoing platform study evaluating multiple treatments in biomarker-selected patients (pts) with rare eOC that tends to respond less well to standard therapies. We report interim results from the cobi (MEK1 inhibitor) and atezo (anti-PD-L1) + bev (anti-VEGF) arms.
The present study aims at identifying the association between university students’ academic burnout and undesired behaviors among faculty members at Al-Balqa Applied University from students’ perspectives. A cross-sectional design was used in this study. To collect data, convenience sampling was used to collect data from the study sample. The sample size consisted of 350 undergraduate students from different academic majors at Al-Balqa Applied University. The research instruments included the Maslach Burnout Inventory (MBI), which consists of 22 statements distributed over 3 domains: “emotional exhaustion, depersonalization, and low personal accomplishment”, in addition to the scale of the unwanted behavior developed by Magableh and Abu Ghazal (2013) that covers the following domains: “teaching method, personal characteristics of faculty members, relationship with faculty members, faculty members' efficiency, classroom management and organization, motivational stimulation, and evaluation”. Data were analyzed using the Statistical Package of Social Sciences (SPSS) (v. 26, IBM Corp. New York City, USA). Descriptive statistics and parametric tests were used to analyze the gathered data. The results of the study showed that there is a significant statistical association between faculty members’ undesired behaviors and students’ academic burnout (r=0.361). The study concluded that faculty members’ undesired behaviors should be addressed to alleviate their impact on student's academic and psychological status. The study recommended conducting further awareness campaigns about coping strategies to alleviate the levels of emotional exhaustion, depersonalization, and low personal accomplishment. Keywords: academic burnout, undesired behaviors, emotional exhaustion, university students